Debio 1454 is a FabI inhibitor targeting a combination of enteric bacteria species, A. baumannii, Enterobacter Spp., Klebsiella pneumoniae and E.coli. This compound belongs to a family of narrow-spectrum antiobiotics that combines a very potent activity on pathogens of interest while reducing the selective pressure on other bacterial strains and sparing the microbiome.
May 14, 2019
Debiopharm awarded $2.1 million from CARB-X in the fight against a highly resistant nosocomial-pneumonia causing superbug
June 26, 2014
Debiopharm Group™ and Nobelex Biotech start two collaborations on development of new antibiotics against N. gonorrhoeae and enteric species